MIACALCIN INJECTION Rx
Generic Name and Formulations:
Calcitonin-salmon 200 IU/mL; soln for SC or IM inj.
Indications for MIACALCIN INJECTION:
Paget's disease of bone. Hypercalcemia. Postmenopausal osteoporosis in women >5yrs postmenopausal.
Give by IM inj across multiple sites if total dose >2mL. Paget's: 100 IU SC or IM daily. Hypercalcemia: initially 4 IU/kg SC or IM every 12hrs, may increase after 1–2 days to 8 IU/kg every 12hrs, and then after 2 more days to max 8 IU/kg every 6hrs. Postmenopausal osteoporosis: 100 IU SC or IM daily.
Correct hypocalcemia and other mineral metabolism disorders before initiating; monitor serum calcium and hypocalcemia symptoms during therapy. Increased risk of malignancies. Consider periodic exams of urine sediment; serum alkaline phosphatase and urinary hydroxyproline in Paget's. Postmenopausal osteoporosis: supplement diet with calcium 1g/day and Vit.D 400 IU/day. Re-evaluate periodically. Pregnancy. Nursing mothers.
May antagonize lithium (consider lithium dose adjustment).
Nausea, vomiting, local inflammation, flushing, rash; hypersensitivity reactions, anaphylaxis, hypocalcemia, antibody formation.
Multi-dose vials (2mL)—1
Neurology Advisor Articles
- Excess Abdominal Obesity Linked to Severe Disability in Multiple Sclerosis
- Change in Dietary Patterns Over 5 Years in Early Multiple Sclerosis
- High-Dose Biotin May Be an Effective Treatment for Progressive MS
- Biobank Data Suggest Vitamin D Reduces Risk for Multiple Sclerosis
- Poor Functional Outcomes Tied to Depressive Symptoms in Multiple Sclerosis
- Oxidized Low-Density Lipoprotein May Predict Risk for Recurrent Stroke
- Inappropriate Prescribing Protocols in Parkinson Disease
- Physical Activity Decreases Vascular Comorbidities in Multiple Sclerosis
- Review of Factors Impacting Sport-Related Concussion Headaches
- Congress Passes Bill to Fight Opioid Crisis